Related Experiment Video
Updated: Mar 12, 2026
Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation
Ziad Hijazi1,2, Jonas Oldgren3,2, Agneta Siegbahn2,4
1Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Ziad.Hijazi@ucr.uu.se.
Insights
Biomarkers can help predict outcomes in atrial fibrillation (AF). Measuring these markers may improve risk assessment and treatment strategies for stroke, bleeding, and mortality in AF patients.
Area of Science:
- Cardiology
- Biomarker Discovery
- Clinical Risk Assessment
Background:
- Atrial fibrillation (AF) is a prevalent arrhythmia linked to significant cardiovascular risks.
- Current strategies aim to balance stroke prevention with bleeding risks during anticoagulation.
- Novel biomarkers offer insights into cellular stress and organ dysfunction in cardiovascular disease.
Purpose of the Study:
- To explore the utility of circulating biomarkers in patients with atrial fibrillation.
- To assess the association of biomarkers with pathophysiology, clinical outcomes, and treatment effects.
- To determine if biomarker measurements can enhance understanding and management of AF.
Main Methods:
- Measurement of various circulating biomarkers including troponin, natriuretic peptides, GDF-15, galectin-3, creatinine, cystatin C, CRP, cytokines, and d-dimer.
- Analysis of associations between biomarker levels and underlying pathophysiology in AF.
- Evaluation of the relationship between biomarkers and clinical outcomes, including stroke and bleeding.
- Assessment of biomarker response to treatment interventions.
Main Results:
- Biomarkers of myocardial injury, stress, dysfunction, fibrosis, renal dysfunction, inflammation, and coagulation are linked to AF pathophysiology.
- Specific biomarkers have demonstrated associations with adverse clinical outcomes in AF patients.
- Biomarker levels may reflect treatment effects, suggesting potential for personalized therapy.
Conclusions:
- Biomarkers show promise for risk stratification in atrial fibrillation patients.
- These markers can aid in evaluating patients and selecting optimal treatments to prevent stroke, bleeding, and mortality.
- Further research into biomarker-guided therapy may improve patient management and outcomes.
Background:
Atrial fibrillation is the most common sustained arrhythmia and an important contributor to cardiovascular morbidity and mortality. Several strategies have been proposed for prediction of outcomes and individualization of treatments to better balance the benefits of stroke prevention and risks of bleeding during anticoagulation.
Content:
The availability of analytically more specific and sensitive methods to measure circulating biomarkers of cellular and organ stress and dysfunction has led to testing of their utility in several cardiovascular conditions. In patients with atrial fibrillation, biomarkers of myocardial injury (troponin) and cardiovascular stress and dysfunction (natriuretic peptides, growth differentiation factor 15), myocardial fibrosis (galectin-3), renal dysfunction (creatinine, cystatin C), inflammation (C-reactive protein, cytokines) and coagulation activity (d-dimer) have been found associated with underlying pathophysiology, clinical outcomes and effects of treatment. Measurements of these markers might therefore expand the understanding of the pathophysiology, improve risk assessment and optimize treatment in individual patients with atrial fibrillation.
Summary:
Biomarkers for risk stratification have potential roles as tools for evaluation of patients with atrial fibrillation and for selection of the best treatment strategies to prevent stroke, major bleeding, and mortality.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:30Dysrhythmias V: Evaluating Dysrhythmias
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT